Goldman Sachs Upgrades Agilent, Bruker; Lowers Cepheid, LabCorp | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs has upgraded the stock of Agilent Technologies and Bruker, but downgraded Cepheid and Laboratory Corporation of America.

In a report released Sunday about the impending fiscal cliff as well as the global macroeconomic picture, analyst Isaac Ro upgraded the stocks of both Agilent and Bruker to a Buy rating from Neutral, but lowered Cepheid to Neutral from Buy and LabCorp to Sell from Neutral.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.